Clinical trial NCT02127372 (phase 1/phase 2, status: terminated)
Conditions: non-small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: docetaxel, cisplatin and sti571, docetaxel, cisplatin
SMILES: [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H], [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Reason stopped: 
    the study was closed due to poor accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Patients must have histologically or cytologically recurrent, or advanced NSCLC: Stage
             IV disease; or Stage IIIB due to malignant pleural effusion is allowed- only if
             successfully pleurodesed.

          -  Tumor tissue slides must express phosophorylated pdgf-rB by IHC.

          -  At least one measurable target lesion as defined by RECIST criteria that has not been
             irradiated.

          -  No prior chemotherapy treatment for this disease will be allowed. Patients with brain
             metastasis will have to be, after appropriate treatment, neurologically stable for at
             least 1-2 weeks (off steroids) prior to study enrollment.

          -  ECOG performance status 0-1.

          -  Meets initial laboratory parameters.

          -  Men and women of childbearing potential must be willing to consent to using effective
             contraception while on treatment and for at least 3 months thereafter.

        Exclusion Criteria

          -  Any prior treatment with a biologic response modifier or chemotherapeutic agent for
             this disease.

          -  Any concomitant malignancy except non-melanoma skin cancer or in-situ carcinoma of the
             cervix.

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to STI571 and/or docetaxel, or other drugs formulated with polysorbate 80
             and/or cisplatin.

          -  Patients with:

               -  Contrast allergy.

               -  GI bleed ≤ 1 month from study enrollment.

               -  Intermittent or chronic oxygen requirements.

               -  Pulse oximetry <90%.

               -  Grade 3 dyspnea.

               -  History of poorly regulated anticoagulation with warfarin.

               -  Edema or fluid retention grade >1.

               -  Neuropathy grade ≥1.

          -  Uncontrolled inter-current medical illness including, but not limited to, ongoing or
             active infection requiring IV antibiotics, symptomatic congestive heart failure,
             unstable angina pectoris, ≤3 months myocardial infarction or cardiac arrhythmia.

          -  Psychiatric illness/social situations that would limit compliance with study
             requirement or that would prevent informed consent or psychiatric illness/social
             situations requiring inpatient treatment within the past 3 months.

          -  Any type of hearing impairment.

          -  Known HIV infection.

          -  Receiving other investigational agents.